How big is Veracyte, Inc.?

As of Jun 18, Veracyte, Inc. has a market capitalization of $2.1 billion, with net sales of $463.39 million and a net profit of $33.04 million over the last four quarters.

Market Cap: <BR>As of Jun 18, Veracyte, Inc. has a market capitalization of 2,095.70 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, Veracyte, Inc. reported net sales of 463.39 million and a net profit of 33.04 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Dec 24, the company reported shareholder's funds of 1,175.97 million and total assets of 1,334.02 million.

What does Veracyte, Inc. do?

Veracyte, Inc. is a genomic diagnostics company in the Pharmaceuticals & Biotechnology sector, with a market cap of approximately $2.1 billion. As of March 2025, it reported net sales of $114 million and a net profit of $7 million.

Overview: <BR>Veracyte, Inc. is a genomic diagnostics company operating in the Pharmaceuticals & Biotechnology industry, with a market cap in the small-cap bracket.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 114 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 7 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,095.70 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 56.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.23 <BR>Return on Equity: 3.21% <BR>Price to Book: 1.75<BR><BR>Contact Details: <BR>Address: 6000 Shoreline Ct Ste 300, SOUTH SAN FRANCISCO CA: 94080-7606 <BR>Tel: ['1 650 2436300', '1 650 3804413'] <BR>Fax: 1 650 2436301 <BR>Website: https://www.veracyte.com/

Should I buy, sell or hold Veracyte, Inc.?

Who are in the management team of Veracyte, Inc.?

As of March 2022, Veracyte, Inc.'s management team includes Ms. Bonnie Anderson as Chairman and CEO, along with Mr. John Bishop (Lead Independent Director), Mr. Jens Holstein, Dr. Frederick Cohen, Ms. Karin Eastham, and Dr. Robert Epstein as Directors.

As of March 2022, the management team of Veracyte, Inc. includes Ms. Bonnie Anderson, who serves as the Chairman of the Board and Chief Executive Officer. Other members of the Board of Directors are Mr. John Bishop, the Lead Independent Director; Mr. Jens Holstein, a Director; Dr. Frederick Cohen, an Independent Director; Ms. Karin Eastham, an Independent Director; and Dr. Robert Epstein, also an Independent Director.

Is Veracyte, Inc. technically bullish or bearish?

As of October 3, 2025, Veracyte, Inc. shows a mildly bullish trend driven by strong weekly indicators, despite mixed signals in longer time frames and a recent outperformance against the S&P 500.

As of 3 October 2025, the technical trend for Veracyte, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, supported by bullish Bollinger Bands and a mildly bullish monthly Dow Theory. However, the monthly MACD and KST are mildly bearish, and the daily moving averages indicate a mildly bearish stance. The stock has outperformed the S&P 500 over the past week and month, returning 7.23% and 11.13% respectively, while it has underperformed on a year-to-date and one-year basis. Overall, the current technical stance is mildly bullish, driven primarily by strong weekly indicators despite some mixed signals in longer time frames.

Is Veracyte, Inc. overvalued or undervalued?

As of October 24, 2025, Veracyte, Inc. is considered undervalued with attractive metrics, including a P/E ratio of 56 and a PEG ratio of 0.12, despite a 12.05% stock return over the past year, which is lower than the S&P 500's 16.90%, but it has outperformed the index over three years with a return of 128.70%.

As of 24 October 2025, the valuation grade for Veracyte, Inc. has moved from expensive to attractive, indicating a shift towards a more favorable assessment. The company appears to be undervalued based on its current metrics, particularly with a P/E ratio of 56, a PEG ratio of 0.12, and an EV to EBITDA ratio of 35.87, which are relatively appealing compared to its peers. For instance, iRhythm Technologies, Inc. has a significantly higher P/E of -111.60, while TransMedics Group, Inc. shows a P/E of 50.23, suggesting that Veracyte is better positioned in terms of valuation.<BR><BR>In terms of recent performance, Veracyte's stock has returned 12.05% over the past year, which is notably lower than the S&P 500's return of 16.90%, but it has outperformed the index over the last three years with a return of 128.70% compared to 78.85%. This performance, alongside its attractive valuation metrics, reinforces the conclusion that Veracyte, Inc. is currently undervalued in the market.